MHRA just approved Nerandomilast for pulmonary fibrosis. Here's what it means for healthcare regulation in the UK pharmaceutical sector.

The regulatory landscape is shifting across energy, finance, and technology as authorities increase scrutiny. Today's updates highlight enforcement in utilities alongside evolving data privacy standards for artificial intelligence. Maintaining awareness of these changes is essential for ensuring operational compliance within an increasingly scrutinized global market.

1️⃣ Medicines and Healthcare products Regulatory Agency — Nerandomilast (Jascayd) approved for Idiopathic Pulmonary Fibrosis
The regulator granted marketing authorization for this medication to treat adults with progressive pulmonary fibrosis types.
This decision impacts pharmaceutical manufacturers and healthcare providers specializing in the delivery of long-term respiratory care.
Clinical rollout will begin immediately as providers integrate the new treatment into their standard therapeutic protocols.

2️⃣ Ofwat — Severn Trent Water found in breach of wastewater obligations
An enforcement decision was issued after investigations revealed failures in managing regulated wastewater systems across the region.
The ruling hits Severn Trent Water and serves as a sharp warning to other utility providers regarding maintenance.
The company must implement mandatory remedial actions and may face financial penalties for these environmental breaches.

3️⃣ Health and Safety Executive — Prosecution Notice following worker death from wall panel collapse
The HSE issued a formal notice after a worker was killed during the dismantling of heavy cleanroom wall panels.
This development affects construction and maintenance firms involved in high-risk site decommissioning and industrial dismantling projects.
The regulator is pursuing legal action to ensure much stricter adherence to safety protocols during complex hazardous activities.

4️⃣ Bank of England — Proposed fees regime for financial market infrastructure supervision
A new policy statement outlines supervisory fees for central counterparties and central securities depositories for the 2026/27 period.
The regime hits financial market infrastructures operating within the UK jurisdiction and participating in the updated fee cycle.
Firms must adjust their regulatory budgets to align with finalized fee structures for the upcoming supervision year.

Full analysis in the attached RegNext Daily Europe Radar carousel.

— Elena Navarro · Managing Editor, RegNext
Daily Europe Radar · Wednesday 08 Jul 2026
#EURegulation #UKRegulation #FinancialRegulation #ComplianceIntelligence